Latest news with #GordonDownie
Yahoo
20-05-2025
- Health
- Yahoo
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
SAN ANTONIO, May 20, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved research programs, and served in national leadership roles with the American College of Chest Physicians in the areas of interventional pulmonology, lung cancer, and medical ethics. "It's a privilege to join bioAffinity at such a pivotal time," Dr. Downie said. "I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making. I'm excited by the opportunity to expand access to this innovative technology that can save lives." In 2007, Dr. Downie left academia and opened a pulmonology practice in rural East Texas, an underserved area with limited access to healthcare. The lack of pulmonary care is exacerbated by an aging population and rising rates of lung disease, including COPD. Most recently, he was the Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center. Dr. Downie earned his PhD in experimental pathology from the State University of New York at Buffalo (SUNY Buffalo) and his medical degree from Northwestern University. He completed residency and fellowship training at the University of North Carolina at Chapel Hill, and subsequently served on the faculty at SUNY Buffalo and the Brody School of Medicine at East Carolina University. "Dr. Downie brings a rare blend of clinical excellence, research insight, and innovation in delivery of care," said Maria Zannes, President and CEO of bioAffinity Technologies. "His depth of experience in interventional pulmonology and his passion for early cancer detection make him the ideal leader to guide our clinical strategy as we scale CyPath® Lung and expand our diagnostic platform to additional diseases." Prior to pursuing his career in medicine, Dr. Downie was an Olympic bronze medalist at the 1976 Summer Olympics in Montreal as part of Great Britain's men's 4×200-meter freestyle relay swim team. He also won silver and bronze medals at the 1975 World Aquatics Championships and was a four-time NCAA All-American swimmer for the University of Michigan. "It's that same spirit of commitment and discipline that has made Dr. Downie a world-class physician respected by his peers throughout the country," Ms. Zannes said. "We are delighted to welcome him to bioAffinity." About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CyPath® Lung's usefulness in managing indeterminate lung nodules by filling a critical gap in clinical decision-making, expanding access to CyPath® Lung technology to save lives, Dr. Downie's contribution to scaling CyPath® Lung, and expanding the Company's diagnostic platform to additional diseases. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to accelerate the commercial growth of CyPath® Lung, Dr. Downie's ability to help expand access to CyPath® Lung technology and guide the Company's clinical strategy, the Company's ability to advance new diagnostics for additional diseases, and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@
Business Wire
20-05-2025
- Health
- Business Wire
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. 'I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making." Share Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved research programs, and served in national leadership roles with the American College of Chest Physicians in the areas of interventional pulmonology, lung cancer, and medical ethics. 'It's a privilege to join bioAffinity at such a pivotal time,' Dr. Downie said. 'I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making. I'm excited by the opportunity to expand access to this innovative technology that can save lives.' In 2007, Dr. Downie left academia and opened a pulmonology practice in rural East Texas, an underserved area with limited access to healthcare. The lack of pulmonary care is exacerbated by an aging population and rising rates of lung disease, including COPD. Most recently, he was the Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center. Dr. Downie earned his PhD in experimental pathology from the State University of New York at Buffalo (SUNY Buffalo) and his medical degree from Northwestern University. He completed residency and fellowship training at the University of North Carolina at Chapel Hill, and subsequently served on the faculty at SUNY Buffalo and the Brody School of Medicine at East Carolina University. 'Dr. Downie brings a rare blend of clinical excellence, research insight, and innovation in delivery of care,' said Maria Zannes, President and CEO of bioAffinity Technologies. 'His depth of experience in interventional pulmonology and his passion for early cancer detection make him the ideal leader to guide our clinical strategy as we scale CyPath® Lung and expand our diagnostic platform to additional diseases.' Prior to pursuing his career in medicine, Dr. Downie was an Olympic bronze medalist at the 1976 Summer Olympics in Montreal as part of Great Britain's men's 4×200-meter freestyle relay swim team. He also won silver and bronze medals at the 1975 World Aquatics Championships and was a four-time NCAA All-American swimmer for the University of Michigan. 'It's that same spirit of commitment and discipline that has made Dr. Downie a world-class physician respected by his peers throughout the country,' Ms. Zannes said. 'We are delighted to welcome him to bioAffinity.' About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CyPath® Lung's usefulness in managing indeterminate lung nodules by filling a critical gap in clinical decision-making, expanding access to CyPath® Lung technology to save lives, Dr. Downie's contribution to scaling CyPath® Lung, and expanding the Company's diagnostic platform to additional diseases. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to accelerate the commercial growth of CyPath® Lung, Dr. Downie's ability to help expand access to CyPath® Lung technology and guide the Company's clinical strategy, the Company's ability to advance new diagnostics for additional diseases, and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Yahoo
08-05-2025
- Health
- Yahoo
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer
Dr. Gordon Downie shares case-based evidence demonstrating how CyPath® Lung improves diagnostic confidence and guides care in high-risk patients SAN ANTONIO, May 08, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced the release of a white paper authored by Dr. Gordon Downie, MD, PhD, Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center. The paper, titled "CyPath® Lung in Practice: Cases 1-4," details real-world clinical cases in which CyPath® Lung, a noninvasive sputum-based test, significantly influenced clinical decision-making for patients with indeterminate pulmonary nodules. A majority of nodules discovered incidentally or through low dose CT screening programs are less than 20 mm. They are considered indeterminate if they cannot be definitively classified as malignant or benign based on imaging alone. "Over the past year, CyPath® Lung has become an active component in our clinical assessment of newly discovered non-calcified pulmonary nodules. It has accelerated diagnosis, helped guide difficult clinical discussions, and prevented unnecessary invasive procedures," Dr. Downie said. The white paper presents four cases involving high-risk patients, including those with: Sub-8 mm nodules in hard-to-biopsy locations A prior cancer history complicating imaging interpretation Post-COVID pulmonary changes and indeterminate PET scans A previous lung cancer diagnosis with new suspicious imaging findings In each scenario, CyPath® Lung played a pivotal role in determining next steps for patients ranging from the active surveillance of the "watch and wait" approach to more proactive invasive procedures that carry their own risks. "As more high-risk patients are screened, we are seeing an explosion in lung nodules, 98% of which we know are benign. But we don't want to miss that remaining 2%," Dr. Downie said. "Adding CyPath® Lung as an adjuvant after imaging by low dose CT and PET provides real-time information about the likelihood of malignancy. Now my patients and I can make a more informed decision about whether to continue to monitor the nodules or proceed with further evaluation, including biopsy." "Dr. Downie's clinical insights and impactful white paper confirm the value of adding CyPath® Lung to the standard of care for physicians navigating the complexities of pulmonary nodules in high-risk patients," said Maria Zannes, President and CEO of bioAffinity Technologies. "We are most appreciative of him sharing his experience with CyPath® Lung by highlighting the impact on real people with very real feelings and fears around the subject of cancer." The full white paper is available on About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding physicians using CyPath® Lung to make more informed decisions about whether to continue to monitor lung nodules or proceed with further evaluation, including biopsy. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to continue to confirm the value of adding CyPath® Lung to the standard of care for physicians navigating the complexities of pulmonary nodules in high-risk patients and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@
Business Wire
08-05-2025
- Health
- Business Wire
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced the release of a white paper authored by Dr. Gordon Downie, MD, PhD, Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center. Real-world clinical cases demonstrate how CyPath® Lung improves diagnostic confidence and guides care in patients with indeterminate pulmonary nodules. The paper, titled ' CyPath® Lung in Practice: Cases 1-4,' details real-world clinical cases in which CyPath® Lung, a noninvasive sputum-based test, significantly influenced clinical decision-making for patients with indeterminate pulmonary nodules. A majority of nodules discovered incidentally or through low dose CT screening programs are less than 20 mm. They are considered indeterminate if they cannot be definitively classified as malignant or benign based on imaging alone. 'Over the past year, CyPath® Lung has become an active component in our clinical assessment of newly discovered non-calcified pulmonary nodules. It has accelerated diagnosis, helped guide difficult clinical discussions, and prevented unnecessary invasive procedures,' Dr. Downie said. The white paper presents four cases involving high-risk patients, including those with: Sub-8 mm nodules in hard-to-biopsy locations A prior cancer history complicating imaging interpretation Post-COVID pulmonary changes and indeterminate PET scans A previous lung cancer diagnosis with new suspicious imaging findings In each scenario, CyPath® Lung played a pivotal role in determining next steps for patients ranging from the active surveillance of the 'watch and wait' approach to more proactive invasive procedures that carry their own risks. 'As more high-risk patients are screened, we are seeing an explosion in lung nodules, 98% of which we know are benign. But we don't want to miss that remaining 2%,' Dr. Downie said. 'Adding CyPath® Lung as an adjuvant after imaging by low dose CT and PET provides real-time information about the likelihood of malignancy. Now my patients and I can make a more informed decision about whether to continue to monitor the nodules or proceed with further evaluation, including biopsy.' 'Dr. Downie's clinical insights and impactful white paper confirm the value of adding CyPath® Lung to the standard of care for physicians navigating the complexities of pulmonary nodules in high-risk patients,' said Maria Zannes, President and CEO of bioAffinity Technologies. 'We are most appreciative of him sharing his experience with CyPath® Lung by highlighting the impact on real people with very real feelings and fears around the subject of cancer.' The full white paper is available on About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding physicians using CyPath® Lung to make more informed decisions about whether to continue to monitor lung nodules or proceed with further evaluation, including biopsy. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to continue to confirm the value of adding CyPath® Lung to the standard of care for physicians navigating the complexities of pulmonary nodules in high-risk patients and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
